Found 370 clinical trials
SafeBoosC III Two-year Follow-up
The SafeBoosC-III 2 year follow up study will follow up on all patients randomised in the SafeBoosC-III clinical trial (NCT03770741). The investigators will collect data when the patients are two years of corrected age from routine standardised follow up assessments, parental questionnaires as well as informal assessments. The study will …
- 0 views
- 25 Apr, 2025
- 1 location
- Online study
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland were opened for …
- 0 views
- 14 Mar, 2022
- 1 location
- Online study
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) (phaethuSA)
Study visit frequency: every 2 weeks in the treatment period and every 4 weeks in the follow-up period. The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up period.
- 0 views
- 17 Nov, 2021
- 28 locations
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
In this case, participation will be for 79 weeks including the screening period.
- 0 views
- 17 Nov, 2021
- 3 locations
Happy Hands Pilot Study
Patient-reported outcomes and grip strength will be collected before and after the 12 week intervention period. Change in pain, stiffness, grip strength, disease activity and quality indicators will be assessed after 12 weeks.
- 0 views
- 09 Dec, 2021
- 2 locations
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
Thirty patients with AIDS or AIDS related complex (ARC) are entered into the study to receive an increasing schedule of three dosage levels of intranasal peptide T for 12 - 16 weeks followed by a 1-month off-drug follow-up period and a subsequent 1-month return to the drug. All patients receive …
- 0 views
- 06 Sep, 2024
- 3 locations
A Mobile Application for Telerehabilitation in Parkinson's Disease
The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease.
- 20 views
- 16 Feb, 2024
- 1 location
Cognitive Behavioural Therapy (CBT) for Chronic Loneliness in Children and Young People
Loneliness is a significant problem for young people and is associated with a range of physical and mental health difficulties. Meta-analyses have identified that interventions aimed at young people who report loneliness as their primary problem are lacking within the literature. In adults, the most effective interventions for loneliness are …
- 0 views
- 09 Dec, 2021
- 1 location
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …
- 0 views
- 23 Nov, 2021
- 23 locations
IPG7236 in Patients With Advanced Solid Tumors
The study will include a dose escalation phase (Part 1) and a dose expansion phase (Part 2). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose.
- 0 views
- 14 Mar, 2022
- 1 location